EcoDrugPlus

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSMAUG00000006269
Gene Symbol: HTR1F
4 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMAUG00000011880
Gene Symbol: HTR2A
2 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSMAUG00000015125
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMAUG00000010378
Gene Symbol: HTR3A
4 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMAUG00000010708
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMAUG00000006143
Gene Symbol: HTR4
4 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSMAUG00000001772
Gene Symbol: HTR5A
4 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMAUG00000008537
Gene Symbol: HTR7
3 Cross references
219 Possible Orthologues:

60s Ribosomal Protein L11

Ensembl ID : ENSMAUG00000002975
Gene Symbol: LOC101827706
3 Cross references
117 Possible Orthologues:

60s Ribosomal Protein L28

Ensembl ID : ENSMAUG00000000783
Gene Symbol: LOC101823529
3 Cross references
168 Possible Orthologues:

60s Ribosomal Protein L32

Ensembl ID : ENSMAUG00000009858
Gene Symbol: LOC101825055
3 Cross references
232 Possible Orthologues:

60s Ribosomal Protein L36a-Like

Ensembl ID : ENSMAUG00000003759
Gene Symbol: LOC101829910
3 Cross references
62 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).